Haleon

Haleon plc
Company typePublic limited company
ISINGB00BMX86B70
Industry
Predecessors
Founded18 July 2022; 2 years ago (2022-07-18)
HeadquartersWeybridge, England, United Kingdom
Area served
Worldwide
Key people
Products
Brands
RevenueIncrease £11,302 million (2023)[1]
Increase £1,996 million (2023)[1]
Decrease £1,111 million (2023)[1]
Total assetsDecrease £34,055 million (2023)[1]
Total equityIncrease £16,729 million (2023)[1]
Number of employees
24,000 (2023)[2]
Websitewww.haleon.com

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England.[3] It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins.[4] The company was projected to be a global leader in over the counter medicines with a 7.3 percent market share in 2022.[5]

Haleon was established on 18 July 2022 as a corporate spin-off from GSK.[6]

Sir David Lewis is chairman, with Brian McNamara as CEO.[7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020.[5]

  1. ^ a b c d e "Annual results 2023" (PDF). Haleon. Retrieved 29 February 2024.
  2. ^ "Haleon plots massive layoffs in UK and beyond to save costs: report". Fierce Pharma. 13 July 2023. Retrieved 11 February 2024.
  3. ^ "GSK announces independent Consumer Healthcare company is to be called Haleon | GSK". www.gsk.com. 22 February 2022. Retrieved 21 February 2023.
  4. ^ Ralph, Alex (2 July 2022). "GlaxoSmithKline prepares to get back to basics with historic break-up". The Times. Retrieved 4 July 2022.
  5. ^ a b Cornell, Joe (15 July 2021). "GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022". Forbes. Retrieved 10 June 2022.
  6. ^ "Prospectus" (PDF). GSK plc. p. 15. Archived from the original (PDF) on 1 June 2022. Retrieved 10 June 2022.
  7. ^ Kleinman, Mark (3 May 2022). "GSK's £45bn Panadol and Sensodyne-maker Haleon in talks to hire banks". Sky News. Retrieved 10 June 2022.